Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book highlights novel nano-engineering advances that enable enhanced bone formation at the implant/biomaterial and bone tissue interface, towards bone tissue engineering applications. Spanning a variety of biomaterial categories, from nanofibrous scaffolds (natural and synthetic) to the nanoscale modification of metallic implants, novel bioactive and therapeutic modifications have made it possible to enhance new bone formation, which could be particularly useful for the management of compromised sites.

human tooth powder --- bioceramics --- biocompatibility --- bone regeneration --- vascularization --- nano-composite --- microstructure --- nanoindentation --- bone implants --- powder metallurgy --- calcium orthophosphates --- nano-hydroxyapatite --- eggshell --- cuttlefish bone --- mussel shell --- amorphous calcium carbonate --- hydrogel --- tissue engineering --- biphasic calcium phosphate nanoparticle (BCP-NP) --- biodegradable --- gelatin methacryloyl (GelMA) --- visible light --- inorganic nanomaterials --- nano hydroxyapatites --- nano silica --- metallic nanomaterials --- magnesium and its alloys --- hydroxyapatite --- surface modifications --- titanium implants --- corrosion analysis --- bioactivity --- biomaterial --- bone substitute --- apatite --- microwave-assisted hydrothermal synthesis --- microgeometry --- mechanobiology --- global DNA methylation --- osteoblast mechanosensing --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Are metropolises really the “manifest destiny” of humankind? Is the environmental predicament calling for more concentration and incorporation? Or is it conducive to some kind of urban exodus? By and large, what might be the principles and ethics of design in such a condition? These are some of the issues that this book addresses.

Imagination --- Communication in architectural design --- Théorie de l'architecture --- Processus de conception --- Regional planning --- Environmental aspects --- Architecture --- Philosophy --- Decoration and ornament, Architectural --- Conception architecturale --- Trienal de arquitectura de Lisboa --- 72.078 --- 504 --- Architectuurtentoonstellingen --- Ecologisch bouwen --- Duurzame ontwikkeling --- 72.04 --- Ornamenten (architectuur) --- Decoratie (architectuur) --- 72.017 --- Ruimte (architectuur) --- Lisbon Triennale Millennium bcp Universities Award --- 373.67 --- Architectuuronderzoek --- Agriculture --- Environmental protection --- Landscapes in art --- Rural conditions in art --- Environnement --- Paysages dans l'art --- Conditions rurales dans l'art --- Aspect de l'environnement --- Protection --- Exhibitions --- 728.6 --- 728.6 Plattelandsarchitectuur. Boerderijen --- Plattelandsarchitectuur. Boerderijen --- Agriculture. Animal husbandry. Hunting. Fishery --- Imagination - Exhibitions --- Communication in architectural design - Exhibitions --- Regional planning - Environmental aspects - Exhibitions --- Architecture - Philosophy - Exhibitions --- Decoration and ornament, Architectural - Exhibitions

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.

acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody–drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- n/a --- antibody-drug conjugate